Endolysosomal N-glycan processing is critical to attain the most active form of the enzyme acid alpha-glucosidase-Reference-Cited by-同舟云学术

Endolysosomal N-glycan processing is critical to attain the most active form of the enzyme acid alpha-glucosidase

Published:2021-01 Issue: Volume:296 Page:100769
ISSN:0021-9258
Container-title:Journal of Biological Chemistry
language:en
Short-container-title:Journal of Biological Chemistry

Author:

Selvan Nithya,Mehta Nickita,Venkateswaran Suresh,Brignol Nastry,Graziano Matthew,Sheikh M. Osman,McAnany Yuliya,Hung Finn,Madrid Matthew,Krampetz Renee,Siano Nicholas,Mehta Anuj,Brudvig Jon^ORCID,Gotschall Russell,Weimer Jill M.,Do Hung V.

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Biochemistry

Reference50 articles.

1. alpha-Glucosidase deficiency in generalized glycogenstorage disease (Pompe's disease);Hers;Biochem. J.,1963

2. The role of skeletal muscle glycogen breakdown for regulation of insulin sensitivity by exercise;Jensen;Front. Physiol.,2011

3. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease;Kishnani;J. Pediatr.,2006

4. The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature;van den Hout;Pediatrics,2003

5. Pompe disease: Glycogen storage disease type II, acid α-glucosidase (acid maltase) deficiency;Reuser,2018

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical insight meets scientific innovation to develop a next generation ERT for Pompe disease;Molecular Genetics and Metabolism;2024-09

2. Comments on: Increasing Enzyme Mannose-6-Phosphate Levels but Not Miglustat Coadministration Enhances the Efficacy of Enzyme Replacement Therapy in Pompe Mice;Journal of Pharmacology and Experimental Therapeutics;2024-05-21

3. Failure of Autophagy in Pompe Disease;Biomolecules;2024-05-13

4. 104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07);Journal of Neurology;2024-02-28

5. Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02);Journal of Neurology;2023-12-06